drugset / Trial / NCT00464880

Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

NCT00464880

Phase 1/2 Completed 24 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic nephropathy.

Timeline

Start
2005-09
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg